vs
FirstCash Holdings, Inc.（FCFS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FirstCash Holdings, Inc.的1.5倍（$772.1M vs $501.3M），FirstCash Holdings, Inc.净利率更高（20.8% vs 12.7%，领先8.0%），FirstCash Holdings, Inc.同比增速更快（21.2% vs 5.9%），过去两年FirstCash Holdings, Inc.的营收复合增速更高（16.9% vs 9.0%）
FirstCash Holdings, Inc.是总部位于美国得克萨斯州沃斯堡的典当企业，在美国及拉丁美洲多地运营线下典当零售门店，为纳斯达克证券交易所公开上市企业，在美洲典当服务领域拥有成熟的业务布局与完善的运营网络。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FCFS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$501.3M
营收增速更快
FCFS
高出15.3%
5.9%
净利率更高
FCFS
高出8.0%
12.7%
两年增速更快
FCFS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $501.3M | $772.1M |
| 净利润 | $104.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 28.5% | 14.5% |
| 净利率 | 20.8% | 12.7% |
| 营收同比 | 21.2% | 5.9% |
| 净利润同比 | 24.7% | 3.9% |
| 每股收益（稀释后） | $2.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCFSRVTY
| Q4 25 | $501.3M | $772.1M | ||
| Q3 25 | $411.0M | $698.9M | ||
| Q2 25 | $385.1M | $720.3M | ||
| Q1 25 | $371.1M | $664.8M | ||
| Q4 24 | $413.7M | $729.4M | ||
| Q3 24 | $363.1M | $684.0M | ||
| Q2 24 | $363.5M | $691.7M | ||
| Q1 24 | $366.8M | $649.9M |
净利润FCFSRVTY
| Q4 25 | $104.2M | $98.4M | ||
| Q3 25 | $82.8M | $46.7M | ||
| Q2 25 | $59.8M | $53.9M | ||
| Q1 25 | $83.6M | $42.2M | ||
| Q4 24 | $83.5M | $94.6M | ||
| Q3 24 | $64.8M | $94.4M | ||
| Q2 24 | $49.1M | $55.4M | ||
| Q1 24 | $61.4M | $26.0M |
毛利率FCFSRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FCFSRVTY
| Q4 25 | 28.5% | 14.5% | ||
| Q3 25 | 27.4% | 11.7% | ||
| Q2 25 | 21.1% | 12.6% | ||
| Q1 25 | 30.0% | 10.9% | ||
| Q4 24 | 26.5% | 16.3% | ||
| Q3 24 | 23.5% | 14.3% | ||
| Q2 24 | 18.2% | 12.4% | ||
| Q1 24 | 22.3% | 6.8% |
净利率FCFSRVTY
| Q4 25 | 20.8% | 12.7% | ||
| Q3 25 | 20.1% | 6.7% | ||
| Q2 25 | 15.5% | 7.5% | ||
| Q1 25 | 22.5% | 6.4% | ||
| Q4 24 | 20.2% | 13.0% | ||
| Q3 24 | 17.9% | 13.8% | ||
| Q2 24 | 13.5% | 8.0% | ||
| Q1 24 | 16.7% | 4.0% |
每股收益（稀释后）FCFSRVTY
| Q4 25 | $2.35 | $0.86 | ||
| Q3 25 | $1.86 | $0.40 | ||
| Q2 25 | $1.34 | $0.46 | ||
| Q1 25 | $1.87 | $0.35 | ||
| Q4 24 | $1.86 | $0.77 | ||
| Q3 24 | $1.44 | $0.77 | ||
| Q2 24 | $1.08 | $0.45 | ||
| Q1 24 | $1.35 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $125.2M | $919.9M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $2.3B | $7.3B |
| 总资产 | $5.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资FCFSRVTY
| Q4 25 | $125.2M | $919.9M | ||
| Q3 25 | $130.2M | $931.4M | ||
| Q2 25 | $101.5M | $991.8M | ||
| Q1 25 | $146.0M | $1.1B | ||
| Q4 24 | $175.1M | $1.2B | ||
| Q3 24 | $106.3M | $1.2B | ||
| Q2 24 | $113.7M | $2.0B | ||
| Q1 24 | $135.1M | $1.7B |
总债务FCFSRVTY
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.5B | — |
股东权益FCFSRVTY
| Q4 25 | $2.3B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.1B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B | ||
| Q1 24 | $2.0B | $7.8B |
总资产FCFSRVTY
| Q4 25 | $5.3B | $12.2B | ||
| Q3 25 | $5.2B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.4B | $12.4B | ||
| Q4 24 | $4.5B | $12.4B | ||
| Q3 24 | $4.4B | $12.8B | ||
| Q2 24 | $4.3B | $13.4B | ||
| Q1 24 | $4.2B | $13.4B |
负债/权益比FCFSRVTY
| Q4 25 | 0.98× | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 0.79× | — | ||
| Q1 25 | 0.83× | — | ||
| Q4 24 | 0.85× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 0.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $206.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.98× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FCFSRVTY
| Q4 25 | $206.6M | $182.0M | ||
| Q3 25 | $135.8M | $138.5M | ||
| Q2 25 | $116.9M | $134.3M | ||
| Q1 25 | $126.6M | $128.2M | ||
| Q4 24 | $198.1M | $174.2M | ||
| Q3 24 | $113.1M | $147.9M | ||
| Q2 24 | $106.2M | $158.6M | ||
| Q1 24 | $122.5M | $147.6M |
自由现金流FCFSRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率FCFSRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度FCFSRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率FCFSRVTY
| Q4 25 | 1.98× | 1.85× | ||
| Q3 25 | 1.64× | 2.97× | ||
| Q2 25 | 1.95× | 2.49× | ||
| Q1 25 | 1.51× | 3.03× | ||
| Q4 24 | 2.37× | 1.84× | ||
| Q3 24 | 1.74× | 1.57× | ||
| Q2 24 | 2.16× | 2.87× | ||
| Q1 24 | 2.00× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
